文献速递泌尿男性生殖肿瘤

转移性去势抵抗性前列腺癌中塔拉佐帕尼单药长期获益或耐药的肿瘤基因组探索

Exploration of tumor genomics associated with prolonged benefit from or resistance to talazoparib monotherapy in patients with metastatic castration-resistant prostate cancer.
PubMed 文献 · Eur J Cancer · 2026-09-29

TALAPRO-1 II期试验评估塔拉佐帕尼单药治疗携带HRR基因改变的经治转移性去势抵抗性前列腺癌患者。回顾性分析显示,rPFS≥12个月的患者中94%存在肿瘤BRCA2改变,而rPFS<2个月者仅22%;HRR基因回复突变和新兴PARP1变异可能反映逃逸塔拉佐帕尼合成致死或PARP捕获的选择压力。

要点

  • rPFS≥12个月者94%携带肿瘤BRCA2改变,显著高于rPFS<2个月者的22%。
  • HRR基因回复突变和PARP1截短/结合抑制变异可能在耐药中起作用。
  • 塔拉佐帕尼长期获益与肿瘤BRCA2拷贝数丢失相关。

核心结论

  • 长期获益患者通常表现为肿瘤BRCA2拷贝数丢失。
  • HRR基因回复突变和新兴PARP1变异可能反映逃逸塔拉佐帕尼合成致死和/或PARP捕获的选择压力。

研究设计与样本

  • II期TALAPRO-1试验评估塔拉佐帕尼单药治疗携带HRR基因改变的经治转移性去势抵抗性前列腺癌患者。
  • 在疗效人群(n=104)中按rPFS分组(≥12个月;≥2至<12个月;<2个月)回顾性评估肿瘤基因组。
  • 对第1、9、25周及安全性随访访视的连续循环肿瘤DNA样本使用FoundationOne®Liquid CDx评估突变谱的新发变化。

主要发现

  • 16例rPFS≥12个月患者中15例(94%)存在肿瘤BRCA2改变,而27例rPFS<2个月患者中仅6例(22%)存在(p<0.00001)。
  • 在第25周和/或安全性随访访视可评估新发变异的27例患者中,7例检测到预测恢复HRR基因功能的HRR基因回复突变(BRCA1 n=1,BRCA2 n=5,PALB2 n=1)。
  • 在27例可评估患者中,5例出现预测截短PARP1和/或抑制塔拉佐帕尼结合的新兴PARP1变异。

局限性

  • 肿瘤基因组为回顾性评估。
  • 回复突变和PARP1变异分析仅基于部分可评估患者(27例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Poly(ADP-ribose) polymerase (PARP) inhibition is synthetically lethal in cells with deleterious alterations in DNA damage response genes involved in homologous recombination repair (HRR). Alterations in HRR genes, including BRCA1/2, have been identified in ~25% of prostate cancer samples and linked with worse clinical outcomes. We explored relationships between tumor genetics and prolonged benefit with talazoparib in TALAPRO-1. METHODS: The phase II TALAPRO-1 trial evaluated talazoparib monotherapy in pretreated patients with metastatic castration-resistant prostate cancer with HRR gene alterations. Tumor genetics were retrospectively assessed in subgroups in the efficacy population (n = 104) based on radiographic progression-free survival (rPFS: ≥12 months; ≥2 to <12 months; <2 months). Serial circulating tumor DNA samples from weeks 1, 9, and 25 and the safety follow-up visit (SFUV) were assessed for emergent changes in mutational profiles using FoundationOne®Liquid CDx. RESULTS: Among 16 patients with rPFS ≥ 12 months, 15 (94%) exhibited tumor BRCA2 alterations vs. 6/27 (22%) patients with rPFS < 2 months (p < 0.00001). HRR gene reversions predicted to restore HRR gene function were detected in 7/27 patients (BRCA1 [n = 1], BRCA2 [n = 5], PALB2 [n = 1]) evaluable for emergent variants at week 25 and/or the SFUV. Emergent PARP1 variants predicted to truncate PARP1 and/or inhibit talazoparib binding were evident in 5/27 evaluable patients. CONCLUSION: Patients experiencing prolonged benefit typically exhibited tumor BRCA2 copy number loss. Reversion mutations of HRR genes and emergent PARP1 variants likely reflect selective pressure to escape talazoparib synthetic lethality and/or PARP trapping. GOV IDENTIFIER: NCT03148795.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Castro E, Douglas Laird A, Mehra N, et al. Exploration of tumor genomics associated with prolonged benefit from or resistance to talazoparib monotherapy in patients with metastatic castration-resistant prostate cancer. Eur J Cancer. 2026. PMID: 42849324. doi:10.1016/j.ejca.2026.117079

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。